



# 3

PATENT

THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the application of:	)	Atty Docket No.: 0075.00
Hastedt et al.	)	
	)	Examiner: Unknown
	)	
Application No. 10/032,238	)	Group Art Unit: Unassigned
	)	
Filed: 12/21/2001	)	March 28, 2002
	)	
Title: Storage Stable Powder Compositions of	)	
Interleukin-4 Receptor	)	

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on March 28, 2002.

Signed:

*Kathy Honnert*  
Kathy Honnert

INFORMATION DISCLOSURE STATEMENT

UNDER 37 CFR §1.56, §1.97 and §1.98

Commissioner for Patents  
Washington, DC 20231

Dear Sir:

The references listed in the attached PTO Form 08A and 08B may be material to examination of the above-identified patent application. Applicants submit these references in compliance with their duty of disclosure pursuant to 37 CFR §§1.56, 1.97, and 1.98. The Examiner is requested to make these citations of official record in this application.

This Information Disclosure Statement is not to be construed as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that these references indeed constitute prior art.

Copies of the references are enclosed, as required under 37 CFR §1.98. The references on the attached Form 1449 identified by an asterisk (\*) were previously cited by or submitted to the PTO in a prior application relied upon for an earlier filing date. Accordingly, in compliance with 37 CFR §1.98 (d), copies of these references have not been provided.

Attorney Docket No. 0075.00

This Information Disclosure Statement is being timely filed under 37 CFR §§1.97 and is being filed:

- ☒ within three months of the filing date of a national application; within three months of the date of entry of the national stage as set forth in section 1.491 in an international application; or before the mailing date of a first Office action on the merits (whichever event occurs last);
- ☐ more than three months from the filing date of an application and after the mailing date of a first Office action on the merits, but before the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311 (whichever occurs first), and is accompanied by:
  - ☐ the fee set forth in 37 CFR 1.17(p) for submission of an information disclosure statement under §1.97(c) (\$180.00); or
  - ☐ one of the following statements as specified in 37 CFR 1.97(e) that:
    - ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
    - ☐ no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement; or
- ☐ after the mailing date of either a final action under section 1.113 or a notice of allowance under section 1.311, but on or before the payment of the issue fee, and is accompanied by each of:
  - ☐ the following petition:

Applicant hereby requests consideration of the accompanying information disclosure statement;
  - ☐ the petition fee set forth in 37 CFR 1.17(i) (\$130.00); and
  - ☐ one of the following statements as specified in 37 CFR 1.97(e) that:
    - ☐ each item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three

months prior to the filing of the information disclosure statement; or

☐

no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the statement after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in section 1.56(c) more than three months prior to the filing of the information disclosure statement.

☐

Attached is Check No. \_ in the amount of \$0.

☐

Please charge the amount of \$\_\_\_ to Deposit Account 500348

☒

If it is determined that any additional fees are due, the Commissioner is hereby authorized to charge such fees to Deposit Account 500348

Respectfully submitted,

INHALE THERAPEUTIC SYSTEMS, INC.


Dated:

*March 28, 2002*

By:

*Susan T. Evans*  
Susan T. Evans  
Reg. No. 38,443

San Carlos, CA 94070  
(650) 631-3100



Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE


Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

performance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 See Kind's Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

**Burden Hour Statement:** This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.**



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

PTO/SB/088 (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO		<b>Complete if Known</b>			
		Application Number	10/032,238		
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Filing Date	12/21/2001		
		First Named Inventor	Jayne Hastedt		
		Group Art Unit			
		Examiner Name			
Sheet	1	of	1	Attorney Docket Number	0075.00

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AF	COHN ET AL., "Th2-Induced Airway Mucus Production is Dependent on IL-4R alpha, But Not on Eosinophils," J. Immunol, Vol. 162 ( No. 10), p. 6178-83,	
	AG	BORISH ET AL., "Interleukin-4 Receptor in Moderate Atopic Asthma," Am J Respir Crit Care Med, Vol. 160 ( No. 6), p. 1816-23,	
	AH	CHEN ET AL., "CD4+ T Lymphocyte Modulation of Ozone-Induced Murine Pulmonary Inflammation," Am J Respir Cell Mol Biol, Vol. 12 ( No. 4), p. 396-403,	
	AI	SANGWAN ET AL., "Aerosolized Protein Delivery in Asthma: Gamma Camera Analysis of Regional Deposition and Perfusion," J. Aerosol Med, Vol. 14 ( No. 2), p. 185-95,	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.